- Home
- FOCL vs NRXP Comparison
FOCL vs NRXP Comparison
Compare FOCL & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FOCL | NRXP |
|---|---|---|
| Founded | N/A | 2015 |
| Country | France | United States |
| Employees | 289 | 29 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.7M | 181.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FOCL | NRXP |
|---|---|---|
| Price | $6.13 | $3.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | 44.3K | ★ 753.9K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,547.84 |
| Revenue Next Year | N/A | $1,591.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.76 | $1.65 |
| 52 Week High | $6.18 | $5.06 |
Technical Indicators
Market Signals| Indicator | FOCL | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 88.29 | 39.37 |
| Support Level | $5.30 | $3.45 |
| Resistance Level | N/A | $4.20 |
| Average True Range (ATR) | 0.19 | 0.33 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 93.75 | 0.00 |
Price Performance
Historical ComparisonAbout FOCL EDAP TMS S.A. American Depositary Shares
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.